CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results 
Universal Music Group Rejects Pershing Square Takeover Proposal 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
Costco Q3 Fiscal 2026 Earnings Beat Expectations as Sales and E-Commerce Surge 
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales growth between 16% and 24%, down from 26% in 2024 but aligning with analysts' expectations of around 20%.
Novo Nordisk faces increasing competition from Eli Lilly (NYSE:LLY), a key rival in the weight-loss drug market. Despite this, the company reported strong fourth-quarter results, with operating profit surging 37% to 36.7 billion Danish crowns ($5.12 billion), surpassing analysts' estimates of 33.6 billion. For 2025, the company expects operating profit growth between 19% and 27%, compared to last year's 26%.
Wegovy sales more than doubled in Q4, reaching 19.9 billion crowns, up from 9.6 billion a year earlier and exceeding the 17.3 billion recorded in Q3. The sustained demand underscores the drug’s strong market position, although future growth is expected to decelerate.
As the weight-loss drug market evolves, Novo Nordisk continues to navigate supply constraints and rising competition. Investors remain focused on the company’s long-term outlook as it balances expansion efforts with growing market challenges.
